Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA
Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated...
Source: europapress.es
📰 Christopher Jansen News
Christopher Jansen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Christopher Jansen. Real-time updates on events, politics, business and more.
Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S.
Source: ots.at
Grünenthal Group: Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.Grünenthal is running a global Phase III programme to
Source: finanznachrichten.de
Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running...
Source: prnewswire.com
Grünenthal and King's College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
/PRNewswire/ -- Grünenthal and Kings College London announced a 24 months collaboration to develop microfluidic culture (MFC) models based on human induced...
Source: prnewswire.com
Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines
Somerset, N.J., and Aachen, Germany (PRWEB) March 15, 2023 -- Catalent, the leader in enabling the development and supply of better treatments for patients
Source: prweb.com
Investcorp brings on Suhail Shaikh as co-head of private credit
Suhail Shaikh was appointed co-head of private credit at alternative investment firm Investcorp.
Source: pionline.com
Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
South Africa Nordrhein Westfalen United States Gabriel Baertschi Florian Dieckmann Christopher Jansen
Source: prleap.com
Grünenthal Group: Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine.The programme will be conducted across approx.
South Africa Nordrhein Westfalen United States Gabriel Baertschi Florian Dieckmann Christopher Jansen
Source: finanznachrichten.de
Grünenthal Group: Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million
AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ -- Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin
South Africa Nordrhein Westfalen United States Gabriel Baertschi Florian Dieckmann Christopher Jansen
Source: finanznachrichten.de